[Sodium-iodide cotransporter in gene therapy].
Since cloning (1996) and characterization of the sodium iodide symporter (NaIS) gene, several investigators have studied the possibility of novel cytoreductive gene therapy based on NaIS gene. The NaIS present in membranes of the thyroid cells is responsible for the capacity of the thyroid to concentrate iodide. The strategies of these methods explore NaIS gene transfer into non-thyroidal cancer cells. NaIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro in several non-thyroidal cell lines. Successful transfection with NaIS gene was demonstrated in human ovarian adenocarcinoma, prostatic adenocarcinoma, human glioma, melanoma, colon carcinoma, lung or mammary gland cell lines. NaIS transfected tumor cells accumulated radioiodine highly enough to elicit therapeutic response to 131I in vitro and in vivo. These data have suggested potential role of NaIS as a novel cancer therapy approach for a targeting radiotherapy for non-thyroidal cancers.